

Correction: *ALK inhibitors in ALK-rearranged nonsmall cell lung cancer with and without brain metastases: systematic review and network meta-analysis*

Jiang J, Zhao C, Zhang F, *et al.* ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis. *BMJ Open* 2022;12:e060782. doi:10.1136/bmjopen-2022-060782

This article has been corrected since it was published online. In the discussion section, the first sentence in first paragraph has been changed from “Throughout the recent randomised clinical trials relating second-generation inhibitors, the median PFS with alectinib in the ALEX Study (34.8 months) was significantly improved,³⁵ followed by ensartinib in the eXalt3 Study (25.8 months),³³ and brigatinib in the ALTA-1L Study (24.0 months)” to “Throughout the recent randomized clinical trials relating second-generation inhibitors, the median PFS (independent committee) times were 25.7 months with alectinib of ALEX study, 25.8 months with ensartinib of eXalt3 study, and 24.0 months with brigatinib of ALTA-1L study”.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

BMJ Open 2022;12:e060782corr1. doi:10.1136/bmjopen-2022-060782corr1

